The emerging role of autoimmunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/cfs).
Morris, Gerwyn, Berk, Michael, Galecki, Piotr et al. · Molecular neurobiology · 2014 · DOI
Quick Summary
This study explores how ME/CFS may involve the immune system attacking the body's own tissues (autoimmunity). Researchers found that up to 60% of ME/CFS patients show signs of autoimmune responses, likely triggered by a combination of stress on cells, viral infections, and problems with how the body produces energy. The study identifies several pathways that could lead to these harmful immune reactions and discusses potential treatments.
Why It Matters
Understanding autoimmunity in ME/CFS is critical because it could explain why some patients' symptoms worsen and persist, and it opens potential avenues for treatment targeting immune dysfunction. If autoimmunity is confirmed as a major disease mechanism in a significant subset of patients, this could enable development of more targeted therapies beyond symptomatic management.
Observed Findings
Up to 60% of ME/CFS patients show evidence of autoimmune responses
Elevated pro-inflammatory cytokines (IL-1, TNF-α) and nuclear factor-κB in ME/CFS
Reduced natural killer cell function commonly observed in ME/CFS patients
Increased bacterial translocation documented in ME/CFS
Low ATP production and mitochondrial dysfunction associated with impaired apoptosis
Inferred Conclusions
Multiple interconnected mechanisms in ME/CFS create conditions favoring autoimmunity, including immune dysregulation, viral persistence, metabolic dysfunction, and oxidative damage
Chronic or recurrent viral infections may trigger autoimmune responses through molecular mimicry and bystander activation in susceptible patients
Mitochondrial dysfunction and depleted ATP represent a fundamental driver of failed self-tolerance through inhibition of normal apoptotic pathways
Immunotherapies targeting B cells (rituximab) or broader immune modulation (endotherapia) may be therapeutic options for autoimmune-mediated ME/CFS
Remaining Questions
What proportion of ME/CFS patients with autoimmune markers actually have disease driven by autoimmunity versus harboring autoimmunity as an epiphenomenon?
What This Study Does Not Prove
This review does not establish causation or prove that autoimmunity is the primary driver of ME/CFS in all patients—it describes associations and plausible mechanisms. The finding that up to 60% of patients show autoimmune markers does not mean autoimmunity causes their disease or explains all symptoms. Additionally, the study does not present new experimental data validating these mechanisms in ME/CFS populations.
Which specific viral infections most commonly trigger autoimmune responses in ME/CFS, and are there identifiable genetic or immunologic risk factors for this progression?
How do the proposed autoimmune mechanisms interact with post-exertional malaise and other cardinal ME/CFS features, and do they explain disease exacerbation patterns?
What is the optimal patient selection for rituximab or endotherapia, and what evidence exists for their efficacy in ME/CFS specifically?